ASBMR 2013

October 2013 - Entera presents the "PTH 1-34 Delivered Orally with Novel Drug Delivery Technology - First in Human Results" for its osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Baltimore, Maryland. PTH 1-34 administered orally to healthy volunteers demonstrates consistent enteral absorption with a PK profile characterized by a rapid Tmax and rapid elimination to optimally simulate the desired PTH profile required for its anabolic effect. A dose escalation and optimization of the formulation was performed showing control of Cmax and variability.

pdfSee poster